Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Breakthrough Requests: FDA Adds Quick Screen To Pare Workload

This article was originally published in The Pink Sheet Daily

Executive Summary

Hope is to quickly reject obviously inadequate designation requests, but few meet criteria for dismissal so far.


Related Content

Sponsors, FDA Reviewers To Get More Flexibility Under New User Fee Program
FDA's Breakthrough Bar May Be Set Too Low, Jenkins Says
Breakthrough Designation Can Be 'Lever' For Manufacturing Evolution, FDA Says
Breakthrough In Two Pages: FDA Offers Preliminary Advice
PDUFA Negotiations: Early Communications, Breakthrough Still On Docket
PDUFA VI: Breakthrough Issues Among FDA Priorities
PDUFA VI: FDA Wary Of Industry Proposals With More Metrics
PDUFA Negotiations Begin With FDA Seeking Review System Reform
‘Breakthrough’ Fee Eyed As Deterrent To Frivolous Requests
Investors Like “Breakthrough” Therapies, But Real Test Still To Come


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst